Take a trial of Canada to unlock this pageFind out more

Diagnocure Inc

CUR C$0.015 0.0  50.0%
06/06/16

This company is no longer active. Data may be out of date or incorrect.
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Oct 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue C$m
Operating Profit C$m
Net Profit C$m
EPS Reported C$
EPS Normalised C$
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps C$
Capex ps C$
Free Cashflow ps C$
Last ex-div: 24th Feb, paid: 11th Mar more... Dividends
Dividend ps C$
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc C$m
Working Capital C$m
Net Fixed Assets C$m
Net Debt C$m
Book Value C$m
Average Shares m
Book Value ps C$

FINANCIAL BRIEF: For the three months ended 31 January 2016, DiagnoCure Inc. revenues decreased 6% to C$134K. Net loss increased 29% to C$430K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative increase of 86% to C$505K (expense), Financial expenses decrease of 38% to C$14K (income). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Jan '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Oct 2016
31st Oct 2017

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (C$) (¢) (¢) (C$) (¢) (¢)
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for Diagnocure Inc
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Bloom Burton & Co. Philippa Flint , Zacks Investment , Echelon Wealth Partners Douglas Loe ,

Profile Summary

DiagnoCure, Inc. is a biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml). Its subsidiaries include Catalyst Oncology LP, 9184-6766 Quebec Inc and 9161-6722 Quebec Inc.

No Management Information.

No. of Employees: 10 No. of Shareholders: n/a


Last Annual October 31st, 2015
Last Interim January 31st, 2016
Incorporated December 8, 1994
Public Since November 26, 1996
Shares in Issue 43,040,471
Free Float 34.3m (79.7%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Toronto Stock Exchange
Eligible for an ISA? a SIPP?

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.


Should you buy CUR

Access CUR Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder